Veracyte (VCYT) Cost of Revenue (2012 - 2026)

Veracyte (VCYT) has 15 years of Cost of Revenue data on file, last reported at $27.2 million in Q1 2026.

• Quarterly Cost of Revenue rose 11.05% year-over-year to $27.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.9 million (up 7.03% YoY) and the FY2025 annual result came in at $100.2 million, up 4.96% from the prior year.
• Cost of Revenue grew to $27.2 million in Q1 2026 per VCYT's latest filing, from $25.9 million in the prior quarter.
• The five-year high for Cost of Revenue was $27.2 million in Q1 2026, with the low at $22.6 million in Q3 2024.
• Average Cost of Revenue over 5 years is $24.8 million, with a median of $24.5 million recorded in 2025.
• Year-over-year, Cost of Revenue jumped 45.77% in 2022 and retreated 8.99% in 2024.
• Veracyte's Cost of Revenue stood at $24.1 million in 2022, then advanced by 4.7% to $25.3 million in 2023, then slipped by 1.73% to $24.8 million in 2024, then rose by 4.5% to $25.9 million in 2025, then advanced by 4.69% to $27.2 million in 2026.
• Business Quant data shows VCYT's Cost of Revenue at $27.2 million in Q1 2026, $25.9 million in Q4 2025, and $24.5 million in Q3 2025.